|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||21.58 - 25.95|
|52 Week Range||13.68 - 25.95|
|Beta (5Y Monthly)||0.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 09, 2022 - Mar 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.60|
Subscribe to Yahoo Finance Plus to view Fair Value for SRRALearn more
Gilead Sciences, which sold the drug for $3 million less than three years ago, still could come out a winner if the drug is approved by the FDA for patients with the blood cancer myelofibrosis.
Sierra Oncology reported a late-stage win Tuesday for a bone cancer drug it acquired at a discount — and the biotech stock catapulted.
SAN MATEO, Calif., January 25, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced that it intends to offer and sell $100.0 million of shares of its common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of